| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Phospholipase D | 34 | 2019 | 49 | 7.220 |
Why?
|
| Sirolimus | 15 | 2021 | 70 | 4.320 |
Why?
|
| Phosphatidic Acids | 13 | 2023 | 18 | 4.180 |
Why?
|
| Glutamine | 5 | 2022 | 36 | 2.150 |
Why?
|
| Neoplasms | 15 | 2022 | 1377 | 2.130 |
Why?
|
| Transforming Growth Factor beta | 6 | 2021 | 216 | 1.960 |
Why?
|
| Apoptosis | 19 | 2021 | 1568 | 1.850 |
Why?
|
| Protein Kinases | 9 | 2009 | 100 | 1.770 |
Why?
|
| Multiprotein Complexes | 10 | 2017 | 56 | 1.580 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 5 | 2022 | 56 | 1.460 |
Why?
|
| Cell Line, Tumor | 30 | 2021 | 2676 | 1.400 |
Why?
|
| Signal Transduction | 21 | 2021 | 2157 | 1.390 |
Why?
|
| Amino Acids | 5 | 2023 | 148 | 1.390 |
Why?
|
| Proto-Oncogene Proteins c-akt | 11 | 2022 | 299 | 1.340 |
Why?
|
| ras Proteins | 6 | 2015 | 54 | 1.340 |
Why?
|
| Lysosomes | 2 | 2019 | 86 | 1.180 |
Why?
|
| Retinoblastoma Protein | 2 | 2021 | 29 | 1.150 |
Why?
|
| Cell Survival | 14 | 2018 | 945 | 1.090 |
Why?
|
| Antibiotics, Antineoplastic | 5 | 2016 | 51 | 1.050 |
Why?
|
| Phosphorylation | 15 | 2021 | 986 | 0.990 |
Why?
|
| Proteins | 5 | 2011 | 382 | 0.940 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2021 | 307 | 0.920 |
Why?
|
| Humans | 55 | 2023 | 43102 | 0.850 |
Why?
|
| Fibroblasts | 5 | 2020 | 281 | 0.840 |
Why?
|
| Breast Neoplasms | 10 | 2015 | 1723 | 0.810 |
Why?
|
| G1 Phase | 3 | 2020 | 31 | 0.790 |
Why?
|
| Protein Kinase C | 6 | 2005 | 124 | 0.790 |
Why?
|
| ATP Citrate (pro-S)-Lyase | 1 | 2022 | 2 | 0.770 |
Why?
|
| S Phase | 2 | 2020 | 36 | 0.760 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2020 | 100 | 0.710 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 32 | 0.710 |
Why?
|
| Transcription Factors | 4 | 2010 | 735 | 0.700 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2016 | 159 | 0.680 |
Why?
|
| Prostatic Neoplasms | 2 | 2021 | 1092 | 0.640 |
Why?
|
| Serum Albumin, Bovine | 1 | 2020 | 49 | 0.640 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2014 | 257 | 0.630 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2019 | 3 | 0.620 |
Why?
|
| Plant Oils | 1 | 2019 | 20 | 0.610 |
Why?
|
| Amino Acids, Essential | 1 | 2019 | 1 | 0.610 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2018 | 968 | 0.600 |
Why?
|
| Cell Membrane Permeability | 1 | 2019 | 57 | 0.600 |
Why?
|
| Aldehydes | 1 | 2019 | 70 | 0.600 |
Why?
|
| Phenols | 2 | 2019 | 107 | 0.580 |
Why?
|
| Ribosomal Protein S6 Kinases | 4 | 2013 | 9 | 0.580 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2010 | 200 | 0.570 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2016 | 49 | 0.560 |
Why?
|
| Animals | 27 | 2020 | 16992 | 0.550 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 140 | 0.530 |
Why?
|
| Cell Membrane | 3 | 2016 | 403 | 0.530 |
Why?
|
| Adaptor Proteins, Signal Transducing | 5 | 2013 | 213 | 0.520 |
Why?
|
| ral GTP-Binding Proteins | 4 | 2018 | 8 | 0.500 |
Why?
|
| Citric Acid Cycle | 1 | 2016 | 7 | 0.490 |
Why?
|
| Eukaryotic Initiation Factor-4E | 2 | 2013 | 18 | 0.490 |
Why?
|
| Aspartic Acid | 1 | 2016 | 51 | 0.480 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 495 | 0.470 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2006 | 63 | 0.470 |
Why?
|
| Cell Movement | 4 | 2018 | 655 | 0.470 |
Why?
|
| Glucose | 3 | 2014 | 244 | 0.470 |
Why?
|
| Up-Regulation | 2 | 2018 | 536 | 0.470 |
Why?
|
| Lipid Metabolism | 1 | 2016 | 148 | 0.460 |
Why?
|
| Ribonucleotides | 1 | 2015 | 4 | 0.450 |
Why?
|
| Aminoimidazole Carboxamide | 1 | 2015 | 4 | 0.450 |
Why?
|
| Glutamic Acid | 1 | 2016 | 131 | 0.450 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 3 | 2010 | 39 | 0.440 |
Why?
|
| Cell-Free System | 1 | 2014 | 15 | 0.440 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2015 | 68 | 0.430 |
Why?
|
| Second Messenger Systems | 1 | 2014 | 13 | 0.430 |
Why?
|
| Estrogens | 2 | 2006 | 203 | 0.430 |
Why?
|
| Molecular Biology | 1 | 2014 | 47 | 0.420 |
Why?
|
| Cell Line | 7 | 2020 | 1410 | 0.400 |
Why?
|
| Smad4 Protein | 1 | 2013 | 8 | 0.390 |
Why?
|
| Phosphoproteins | 3 | 2013 | 206 | 0.390 |
Why?
|
| Mammals | 1 | 2013 | 112 | 0.380 |
Why?
|
| Enzyme Activation | 7 | 2015 | 462 | 0.380 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 196 | 0.370 |
Why?
|
| Pancreatic Neoplasms | 2 | 2013 | 218 | 0.370 |
Why?
|
| Lipids | 1 | 2014 | 256 | 0.360 |
Why?
|
| Carrier Proteins | 3 | 2008 | 321 | 0.360 |
Why?
|
| Gene Expression | 1 | 2014 | 701 | 0.340 |
Why?
|
| Culture Media, Serum-Free | 6 | 2007 | 44 | 0.330 |
Why?
|
| Glycolysis | 1 | 2010 | 71 | 0.330 |
Why?
|
| Food | 1 | 2011 | 103 | 0.320 |
Why?
|
| Immediate-Early Proteins | 1 | 2010 | 49 | 0.310 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2015 | 1124 | 0.310 |
Why?
|
| Mice | 12 | 2019 | 6644 | 0.300 |
Why?
|
| Virology | 1 | 2009 | 8 | 0.300 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2010 | 91 | 0.300 |
Why?
|
| Isoenzymes | 4 | 2003 | 168 | 0.300 |
Why?
|
| Cell Proliferation | 4 | 2018 | 1455 | 0.300 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2009 | 220 | 0.290 |
Why?
|
| Gene Knockdown Techniques | 3 | 2014 | 189 | 0.290 |
Why?
|
| Morpholines | 3 | 2015 | 72 | 0.280 |
Why?
|
| Neoplasm Proteins | 2 | 2016 | 228 | 0.280 |
Why?
|
| Chromones | 3 | 2015 | 53 | 0.280 |
Why?
|
| Mutation | 5 | 2021 | 1177 | 0.280 |
Why?
|
| ADP-Ribosylation Factors | 2 | 2011 | 14 | 0.280 |
Why?
|
| Cell Cycle | 3 | 2021 | 346 | 0.280 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2008 | 88 | 0.270 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 166 | 0.270 |
Why?
|
| Protein Binding | 6 | 2016 | 1082 | 0.270 |
Why?
|
| Kidney Neoplasms | 3 | 2016 | 80 | 0.270 |
Why?
|
| Oncogene Protein pp60(v-src) | 3 | 2004 | 10 | 0.260 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2005 | 49 | 0.230 |
Why?
|
| Protein Kinase C-delta | 5 | 2005 | 17 | 0.220 |
Why?
|
| Alcohol Drinking | 1 | 2010 | 609 | 0.220 |
Why?
|
| Embryo, Mammalian | 1 | 2005 | 157 | 0.220 |
Why?
|
| Diacylglycerol Kinase | 2 | 2014 | 2 | 0.210 |
Why?
|
| Insulin | 2 | 2020 | 258 | 0.200 |
Why?
|
| Models, Biological | 4 | 2010 | 712 | 0.200 |
Why?
|
| Cell Division | 5 | 2004 | 311 | 0.200 |
Why?
|
| Blotting, Western | 5 | 2007 | 883 | 0.200 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 1019 | 0.200 |
Why?
|
| Oxaloacetates | 1 | 2022 | 2 | 0.190 |
Why?
|
| Ketoglutaric Acids | 1 | 2022 | 2 | 0.190 |
Why?
|
| Aminooxyacetic Acid | 1 | 2022 | 3 | 0.190 |
Why?
|
| Adenosine Diphosphate Ribose | 1 | 2022 | 4 | 0.190 |
Why?
|
| Genes, ras | 1 | 2003 | 24 | 0.190 |
Why?
|
| Transaminases | 1 | 2022 | 8 | 0.190 |
Why?
|
| Oleic Acids | 1 | 2022 | 11 | 0.190 |
Why?
|
| Glutamates | 1 | 2022 | 23 | 0.190 |
Why?
|
| Poly(ADP-ribose) Polymerases | 4 | 2013 | 79 | 0.190 |
Why?
|
| GTP Phosphohydrolases | 1 | 2003 | 34 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2002 | 10 | 0.190 |
Why?
|
| Genes, src | 1 | 2002 | 3 | 0.190 |
Why?
|
| Tumor Cells, Cultured | 2 | 2019 | 508 | 0.190 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2002 | 9 | 0.180 |
Why?
|
| Cell Size | 1 | 2002 | 46 | 0.180 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 237 | 0.180 |
Why?
|
| History, 21st Century | 2 | 2014 | 83 | 0.180 |
Why?
|
| E2F Transcription Factors | 1 | 2021 | 11 | 0.180 |
Why?
|
| History, 20th Century | 2 | 2014 | 121 | 0.180 |
Why?
|
| Cells, Cultured | 4 | 2019 | 1621 | 0.180 |
Why?
|
| Protein Transport | 3 | 2019 | 296 | 0.170 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2002 | 165 | 0.170 |
Why?
|
| RNA, Small Interfering | 3 | 2008 | 436 | 0.170 |
Why?
|
| Pinocytosis | 1 | 2020 | 10 | 0.170 |
Why?
|
| Adenocarcinoma | 1 | 2003 | 291 | 0.160 |
Why?
|
| Cattle | 2 | 2020 | 498 | 0.160 |
Why?
|
| Oxidative Stress | 1 | 2006 | 1003 | 0.160 |
Why?
|
| Serum | 2 | 2013 | 17 | 0.160 |
Why?
|
| Cell Line, Transformed | 4 | 2004 | 95 | 0.160 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2013 | 134 | 0.150 |
Why?
|
| Necrosis | 1 | 2019 | 54 | 0.150 |
Why?
|
| Cell Death | 1 | 2020 | 278 | 0.150 |
Why?
|
| Cell Cycle Proteins | 3 | 2013 | 241 | 0.150 |
Why?
|
| Rats | 6 | 2004 | 3735 | 0.150 |
Why?
|
| Endocytosis | 1 | 2019 | 118 | 0.150 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 347 | 0.140 |
Why?
|
| Androgens | 1 | 2018 | 106 | 0.130 |
Why?
|
| Oleic Acid | 1 | 2017 | 15 | 0.130 |
Why?
|
| Phosphatidate Phosphatase | 1 | 1996 | 2 | 0.130 |
Why?
|
| Hep G2 Cells | 1 | 2017 | 63 | 0.130 |
Why?
|
| Oncogenes | 2 | 2009 | 44 | 0.130 |
Why?
|
| Epidermal Growth Factor | 1 | 1996 | 70 | 0.130 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2016 | 59 | 0.120 |
Why?
|
| Purine Nucleotides | 1 | 2016 | 3 | 0.120 |
Why?
|
| Pyrimidine Nucleotides | 1 | 2016 | 4 | 0.120 |
Why?
|
| Porphyrins | 2 | 2008 | 57 | 0.120 |
Why?
|
| Amyloid beta-Protein Precursor | 2 | 2006 | 95 | 0.120 |
Why?
|
| Transfection | 3 | 2007 | 532 | 0.120 |
Why?
|
| Cyclin D1 | 1 | 2015 | 44 | 0.110 |
Why?
|
| Male | 3 | 2021 | 23409 | 0.110 |
Why?
|
| Cerulenin | 1 | 2014 | 1 | 0.110 |
Why?
|
| Diphenylamine | 1 | 2014 | 1 | 0.110 |
Why?
|
| Fatty Acid Synthesis Inhibitors | 1 | 2014 | 1 | 0.110 |
Why?
|
| 1-Acylglycerol-3-Phosphate O-Acyltransferase | 1 | 2014 | 1 | 0.110 |
Why?
|
| Lipogenesis | 1 | 2014 | 19 | 0.110 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2014 | 21 | 0.110 |
Why?
|
| Time Factors | 2 | 2013 | 1857 | 0.110 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 234 | 0.110 |
Why?
|
| Estradiol | 2 | 2006 | 268 | 0.100 |
Why?
|
| Garcinia | 1 | 2013 | 5 | 0.100 |
Why?
|
| Sulindac | 1 | 2013 | 9 | 0.100 |
Why?
|
| Benzophenones | 1 | 2013 | 11 | 0.100 |
Why?
|
| Benzamides | 1 | 2014 | 81 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 220 | 0.100 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2006 | 185 | 0.100 |
Why?
|
| Acyltransferases | 1 | 2013 | 22 | 0.100 |
Why?
|
| 3T3 Cells | 2 | 2003 | 64 | 0.100 |
Why?
|
| Cytochrome c Group | 2 | 2002 | 14 | 0.090 |
Why?
|
| Endoplasmic Reticulum | 2 | 2013 | 108 | 0.090 |
Why?
|
| Membrane Proteins | 2 | 2006 | 561 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2003 | 296 | 0.090 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2011 | 8 | 0.090 |
Why?
|
| Glucose Transport Proteins, Facilitative | 1 | 2010 | 13 | 0.080 |
Why?
|
| Down-Regulation | 2 | 2003 | 456 | 0.080 |
Why?
|
| United States | 2 | 2014 | 5205 | 0.080 |
Why?
|
| Neuropeptides | 1 | 2011 | 64 | 0.080 |
Why?
|
| Oxidative Phosphorylation | 1 | 2010 | 60 | 0.080 |
Why?
|
| Plant Extracts | 1 | 2013 | 302 | 0.080 |
Why?
|
| Enzyme Stability | 1 | 2010 | 34 | 0.080 |
Why?
|
| Precipitin Tests | 2 | 2003 | 52 | 0.080 |
Why?
|
| Treatment Outcome | 1 | 2015 | 1604 | 0.080 |
Why?
|
| Enzyme Inhibitors | 2 | 2013 | 458 | 0.080 |
Why?
|
| Mice, Knockout | 4 | 2007 | 1035 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2013 | 137 | 0.080 |
Why?
|
| Retroviridae | 1 | 2009 | 25 | 0.070 |
Why?
|
| Japan | 1 | 2009 | 348 | 0.070 |
Why?
|
| Biphenyl Compounds | 1 | 2008 | 53 | 0.070 |
Why?
|
| Female | 3 | 2017 | 24698 | 0.070 |
Why?
|
| Lignans | 1 | 2008 | 22 | 0.070 |
Why?
|
| Protein Multimerization | 1 | 2008 | 115 | 0.070 |
Why?
|
| Light | 1 | 2008 | 185 | 0.070 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2007 | 5 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 259 | 0.060 |
Why?
|
| Phosphothreonine | 1 | 2006 | 5 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2007 | 69 | 0.060 |
Why?
|
| Phosphoserine | 1 | 2006 | 21 | 0.060 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2006 | 29 | 0.060 |
Why?
|
| Caspases | 2 | 2008 | 148 | 0.060 |
Why?
|
| Neurites | 1 | 2006 | 40 | 0.060 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2005 | 7 | 0.060 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 2003 | 43 | 0.060 |
Why?
|
| Protein Phosphatase 2 | 1 | 2005 | 26 | 0.060 |
Why?
|
| Ribosomes | 1 | 2005 | 35 | 0.060 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 127 | 0.060 |
Why?
|
| Serine | 1 | 2005 | 79 | 0.060 |
Why?
|
| Guinea Pigs | 1 | 2005 | 143 | 0.060 |
Why?
|
| DNA Damage | 2 | 2004 | 356 | 0.060 |
Why?
|
| Thioglycosides | 1 | 2004 | 2 | 0.060 |
Why?
|
| Cricetinae | 1 | 2005 | 241 | 0.060 |
Why?
|
| Dogs | 1 | 2005 | 204 | 0.050 |
Why?
|
| Half-Life | 1 | 2004 | 63 | 0.050 |
Why?
|
| T-Lymphocytes | 1 | 2007 | 386 | 0.050 |
Why?
|
| Photochemotherapy | 1 | 2004 | 43 | 0.050 |
Why?
|
| Tyrosine | 1 | 2004 | 120 | 0.050 |
Why?
|
| Genes, Dominant | 1 | 2003 | 20 | 0.050 |
Why?
|
| Subcellular Fractions | 1 | 2003 | 77 | 0.050 |
Why?
|
| Cyclins | 1 | 2002 | 34 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2002 | 56 | 0.050 |
Why?
|
| Caspase 9 | 1 | 2002 | 30 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2004 | 333 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2004 | 223 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2004 | 277 | 0.050 |
Why?
|
| Plasmids | 1 | 2003 | 244 | 0.050 |
Why?
|
| Disease Progression | 1 | 2004 | 667 | 0.040 |
Why?
|
| Microtubules | 1 | 2002 | 121 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2002 | 183 | 0.040 |
Why?
|
| Kinetics | 1 | 2002 | 695 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2002 | 518 | 0.040 |
Why?
|
| Alzheimer Disease | 1 | 2006 | 1001 | 0.030 |
Why?
|
| Ethylmaleimide | 1 | 1996 | 8 | 0.030 |
Why?
|
| Glycosylation | 2 | 2008 | 113 | 0.030 |
Why?
|
| Presenilin-1 | 2 | 2006 | 28 | 0.030 |
Why?
|
| Curcuma | 1 | 2013 | 5 | 0.030 |
Why?
|
| Butadienes | 1 | 2013 | 29 | 0.030 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 2013 | 10 | 0.030 |
Why?
|
| Heparin | 1 | 2013 | 40 | 0.030 |
Why?
|
| Nitriles | 1 | 2013 | 81 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2013 | 103 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2013 | 195 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2013 | 91 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2013 | 506 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2006 | 1070 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2013 | 434 | 0.020 |
Why?
|
| Antibodies | 1 | 2009 | 144 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2009 | 97 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2008 | 48 | 0.020 |
Why?
|
| Hydrolysis | 1 | 2008 | 97 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2008 | 129 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2008 | 107 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2008 | 224 | 0.020 |
Why?
|
| Allyl Compounds | 1 | 2008 | 55 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2008 | 256 | 0.020 |
Why?
|
| Diglycerides | 1 | 2007 | 9 | 0.020 |
Why?
|
| Golgi Apparatus | 1 | 2007 | 27 | 0.020 |
Why?
|
| Type C Phospholipases | 1 | 2007 | 23 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2007 | 87 | 0.020 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2007 | 34 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2008 | 204 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2008 | 172 | 0.020 |
Why?
|
| Indoles | 1 | 2008 | 187 | 0.020 |
Why?
|
| trans-Golgi Network | 1 | 2006 | 4 | 0.020 |
Why?
|
| Cell Communication | 1 | 2007 | 114 | 0.020 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2006 | 19 | 0.020 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2006 | 35 | 0.020 |
Why?
|
| Endopeptidases | 1 | 2006 | 64 | 0.010 |
Why?
|
| Calcium | 1 | 2008 | 491 | 0.010 |
Why?
|
| Catalysis | 1 | 2006 | 187 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2006 | 101 | 0.010 |
Why?
|
| Mitochondria | 1 | 2008 | 523 | 0.010 |
Why?
|
| src-Family Kinases | 1 | 2004 | 49 | 0.010 |
Why?
|
| Dactinomycin | 1 | 2003 | 11 | 0.010 |
Why?
|
| Phorbol Esters | 1 | 2003 | 8 | 0.010 |
Why?
|
| K562 Cells | 1 | 2003 | 32 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2003 | 150 | 0.010 |
Why?
|
| Luciferases | 1 | 2003 | 71 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2007 | 561 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2004 | 139 | 0.010 |
Why?
|
| Binding Sites | 1 | 2004 | 671 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2003 | 411 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 652 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2007 | 1869 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2003 | 526 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 592 | 0.010 |
Why?
|